

Neerav N Shukla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8385835/publications.pdf>

Version: 2024-02-01

44
papers

3,850
citations

394421

19
h-index

276875

41
g-index

44
all docs

44
docs citations

44
times ranked

9715
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful treatment and integrated genomic analysis of an infant with <i>FIP1L1-RARA</i> fusion-associated myeloid neoplasm. <i>Blood Advances</i> , 2022, 6, 1137-1142.	5.2	4
2	Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 72.e1-72.e8.	1.2	21
3	Acute myeloid leukemia with an fusion in a young child with Down syndrome.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	1.0	3
4	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10001-10001.	1.6	15
5	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	13.2	74
6	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
7	Differential Impact of ALK Mutations in Neuroblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 492-500.	3.0	6
8	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. <i>Molecular Cancer Research</i> , 2021, 19, 1146-1155.	3.4	14
9	Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 830.	7.4	11
10	Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas. <i>Sarcoma</i> , 2021, 2021, 1-7.	1.3	1
11	Identification of a TP53 Deletion in an Undifferentiated Embryonal Sarcoma of the Liver Provides Clinically Relevant Longitudinal Detection of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2021, 5, 1421-1425.	3.0	1
12	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. <i>Journal of Clinical Oncology</i> , 2021, 39, 3822-3828.	1.6	4
13	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. <i>JCO Precision Oncology</i> , 2020, 4, 1280-1284.	3.0	1
14	Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience. <i>Cancer Medicine</i> , 2020, 9, 6093-6101.	2.8	32
15	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. <i>Cancer</i> , 2020, 126, 3114-3121.	4.1	23
16	Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6346-6356.	7.0	75
17	Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 108.	2.8	49
18	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven Cancer. <i>Cancer Discovery</i> , 2019, 9, 605-616.	9.4	11

#	ARTICLE	IF	CITATIONS
19	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019, 134, 2361-2368.	1.4	190
20	Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27500.	1.5	6
21	Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26699.	1.5	16
22	Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 1861-1870.	1.3	12
23	A case of KMT2A-SEPT9 fusion-associated acute megakaryoblastic leukemia. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003426.	1.2	5
24	A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003194.	1.2	32
25	Germline SDHA mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	1.2	33
26	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018, 132, 261-261.	1.4	3
27	Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 79-79.	1.4	0
28	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
29	Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001925.	1.2	17
30	Prognostic factors and survival in non-central nervous system rhabdoid tumors. <i>Journal of Pediatric Surgery</i> , 2017, 52, 373-376.	1.6	10
31	DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. <i>JCO Precision Oncology</i> , 2017, 2017, 1-11.	3.0	37
32	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. <i>JCO Precision Oncology</i> , 2017, 2017, 1-11.	3.0	36
33	Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. <i>Cancer Research</i> , 2016, 76, 4525-4534.	0.9	33
34	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1368-1374.	1.5	49
35	Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia. <i>Blood</i> , 2016, 128, 2780-2780.	1.4	62
36	Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL. <i>Blood</i> , 2015, 126, 2533-2533.	1.4	10

#	ARTICLE	IF	CITATIONS
37	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. <i>Nature Genetics</i> , 2014, 46, 595-600.	21.4	152
38	Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 431-435.	1.5	30
39	Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children's Oncology Group. <i>Frontiers in Oncology</i> , 2013, 3, 141.	2.8	36
40	Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. <i>Cancer</i> , 2012, 118, 3719-3724.	4.1	29
41	Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways. <i>Clinical Cancer Research</i> , 2012, 18, 748-757.	7.0	203
42	Phase II Trial of Clofarabine in Combination with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Pediatric Patients with Refractory or Relapsed Acute Leukemia. <i>Blood</i> , 2012, 120, 1514-1514.	1.4	0
43	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric Patients with Treatment Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia (tMDS/AML). <i>Blood</i> , 2010, 116, 2363-2363.	1.4	0
44	Non-Hodgkin's lymphoma in children and adolescents. <i>Current Oncology Reports</i> , 2006, 8, 387-394.	4.0	15